BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38063316)

  • 1. The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.
    Chen J; Chang X; Li X; Liu J; Wang N; Wu Y; Zheng L; Nie X
    Cancer Med; 2023 Dec; 12(24):21920-21932. PubMed ID: 38063316
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
    J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.
    Wakayama S; Ouchi K; Takahashi S; Yamada Y; Komatsu Y; Shimada K; Yamaguchi T; Shirota H; Takahashi M; Ishioka C
    Clin Colorectal Cancer; 2023 Sep; 22(3):327-338. PubMed ID: 37355363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
    Dallol A; Buhmeida A; Al-Ahwal MS; Al-Maghrabi J; Bajouh O; Al-Khayyat S; Alam R; Abusanad A; Turki R; Elaimi A; Alhadrami HA; Abuzenadah M; Banni H; Al-Qahtani MH; Abuzenadah AM
    J Transl Med; 2016 May; 14(1):118. PubMed ID: 27146902
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA
    JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
    He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
    World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival.
    Zaidi SH; Harrison TA; Phipps AI; Steinfelder R; Trinh QM; Qu C; Banbury BL; Georgeson P; Grasso CS; Giannakis M; Adams JB; Alwers E; Amitay EL; Barfield RT; Berndt SI; Borozan I; Brenner H; Brezina S; Buchanan DD; Cao Y; Chan AT; Chang-Claude J; Connolly CM; Drew DA; Farris AB; Figueiredo JC; French AJ; Fuchs CS; Garraway LA; Gruber S; Guinter MA; Hamilton SR; Harlid S; Heisler LE; Hidaka A; Hopper JL; Huang WY; Huyghe JR; Jenkins MA; Krzyzanowski PM; Lemire M; Lin Y; Luo X; Mardis ER; McPherson JD; Miller JK; Moreno V; Mu XJ; Nishihara R; Papadopoulos N; Pasternack D; Quist MJ; Rafikova A; Reid EEG; Shinbrot E; Shirts BH; Stein LD; Teney CD; Timms L; Um CY; Van Guelpen B; Van Tassel M; Wang X; Wheeler DA; Yung CK; Hsu L; Ogino S; Gsur A; Newcomb PA; Gallinger S; Hoffmeister M; Campbell PT; Thibodeau SN; Sun W; Hudson TJ; Peters U
    Nat Commun; 2020 Jul; 11(1):3644. PubMed ID: 32686686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the landscape of colorectal cancer using targeted deep sequencing.
    Lee CS; Song IH; Lee A; Kang J; Lee YS; Lee IK; Song YS; Lee SH
    Sci Rep; 2021 Apr; 11(1):8154. PubMed ID: 33854094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
    BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
    Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
    Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.